These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38806508)

  • 1. EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients.
    Perelmuter VM; Grigoryeva ES; Savelieva OE; Alifanov VV; Andruhova ES; Zavyalova MV; Bragina OD; Garbukov EY; Menyailo ME; Khozyainova AA; Denisov EV; Cherdyntseva NV; Tashireva LA
    Sci Rep; 2024 May; 14(1):12245. PubMed ID: 38806508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of
    Strati A; Nikolaou M; Georgoulias V; Lianidou ES
    Cells; 2019 Jun; 8(7):. PubMed ID: 31261917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
    Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer.
    Savelieva OE; Tashireva LA; Kaigorodova EV; Buzenkova AV; Mukhamedzhanov RK; Grigoryeva ES; Zavyalova MV; Tarabanovskaya NA; Cherdyntseva NV; Perelmuter VM
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles.
    Wang G; Benasutti H; Jones JF; Shi G; Benchimol M; Pingle S; Kesari S; Yeh Y; Hsieh LE; Liu YT; Elias A; Simberg D
    Colloids Surf B Biointerfaces; 2018 Jan; 161():200-209. PubMed ID: 29080504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
    Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
    Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
    Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
    Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous Manifestations of Epithelial-Mesenchymal Plasticity of Circulating Tumor Cells in Breast Cancer Patients.
    Tashireva LA; Savelieva OE; Grigoryeva ES; Nikitin YV; Denisov EV; Vtorushin SV; Zavyalova MV; Cherdyntseva NV; Perelmuter VM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
    Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
    Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.